Notice of Early Expiration of NIDDK R21 Funding Opportunity Announcements

Notice Number: NOT-DK-20-016

Key Dates
Release Date: April 1, 2020

Related Announcements

PA-18-405: Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21 Clinical Trial Required)

PA-18-720: Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)

PAR-18-857: Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)

PA-18-903: Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)

PAR-18-743: Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)

PAR-18-744: Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)

PAR-19-222: Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)

NOT-DK-20-025

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The purpose of this Notice is to alert potential applicants that NIDDK is expiring the seven R21 FOAs listed below effective September 8, 2020. Applicants who wish to conduct pilot and feasibility trials within the mission of NIDDK may consider using PAS-20-160: Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required).

The expiration date in Part.1 Overview Information, Key Dates section of the FOA below currently reads: Expiration Date: January 8, 2021:

PA-18-405: Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21 Clinical Trial Required).

The expiration dates in Part.1 Overview Information, Key Dates section of the four FOAs below currently read: Expiration Date: May 8, 2021:

PAR-18-743: Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)

PAR-18-744: Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)

PA-18-720: Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)

PAR-19-222: Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)

The expiration dates in Part.1 Overview Information, Key Dates section of the two FOAs below currently read?: Expiration Date: September 8, 2021:

PAR-18-857: Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)
PA-18-903: Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)

All seven of the aforementioned FOA Expiration Dates are modified to readExpiration Date: Sept. 8, 2020

All other aspects of these FOAs remain unchanged.

Inquiries

Please direct all inquiries to:

Barbara Linder, M.D., Ph.D.
Division of Diabetes, Endocrinology and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-0021
Email: linderb@mail.nih.gov

Susan Mendley, M.D.
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-827-1861
Email: susan.mendley@nih.gov

Aynur Unalp-Arida, MD, PhD
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
Telephone: 301-594-8879
Email: aynur.unalp-arida@nih.gov